

Suven Life Sciences Ltd Announces the last patient enrolled in Phase 2 study of SUVN-502 for Moderate Alzheimer's Disease

Top-Line Phase 2 Data on Track for 3Q 2019

HYDERABAD, INDIA (October 25, 2018) -Suven Life Sciences, a specialty biopharmaceutical company developing therapeutics in Central Nervous System diseases, today announced completion of enrollment of patients with **Last-Patient-In** Goal for its Phase 2 POC study of SUVN-502 for moderate Alzheimer's disease.

The company expects to report the top-line data of this study by July/August 2019 time frame.

This randomized, double-blind, placebo-controlled study is evaluating the efficacy and safety of two doses of SUVN-502 in moderate Alzheimer's Disease patients who are taking both Aricept (donepezil) and Namenda (memantine). Study duration is 30 weeks. This is the first ever study to evaluate a triple combination therapy for moderate Alzheimer's disease patients.

There is an urgent need for treatment options for patients with Alzheimer's disease (AD) dementia since there are no new drugs discovered or developed from 2003 till now.

We are very pleased to have completed last patient enrollment, surpassing our target enrollment of 537 patients by enrolling 563 patients in this Phase 2 study in moderate Alzheimer's disease.

Completing patient enrollment in this Phase 2 trial represents a significant milestone in our clinical development plan and moves us a step closer to potentially bringing this new treatment option for people afflicted with moderate Alzheimer's disease globally.

About Suven Life Sciences

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase1 completed SUVN-D4010, Phase 1 commenced SUVN-911 and Phase 1 ready SUVN-I6107.

In addition to these clinical compounds the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.

For more information please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

CIN: L24110TG1989PLC009713

6/F, Serene Chambers, Rd#7, Banjara Hills Hyderabad 500034, India
Tel: 9140 2354 1142 Fax: 9140 2354 1152 Email: info@suven.com